Toggle light / dark theme

In August, the US Air Force Research Laboratory 711th Human Performance Wing launched its iNeuraLS project, an effort to speed up pilot training through brain stimulation.


Some will feel a slight tingling sensation. Others will feel nothing at all.

The electrode placed inside the ear canal isn’t designed to shock. Rather, the US Air Force Research Laboratory (ARFL) believes the earbud-like device, when placed next to the brain’s vagas nerve, will have more of an intellectually stimulating effect. It ought to create moments of super learning, controllable periods of focus that allow pilots to soak up their flight training faster than humanly possible.

Circa 2013


“When the induced field is above a certain threshold, and is directed in an appropriate orientation relative to the brain’s neuronal pathways, localized axonal depolarizations are produced, thus activating the neurons in the relevant brain structure.”

First the machine is calibrated by placing it over a part of the brain that causes the subject’s hand to move. Then the coils are aimed at the brain region under treatment. The treatment lasts about 15 to 30 minutes, repeated over several weeks, and is noninvasive–all the person feels is a slight buzzing, and there are no side effects. This makes it a more palatable relative of other treatments that also target the brain directly, such as electroconvulsive therapy (formerly electroshock), or surgically implanted electrodes.

Summary: Boosting levels of the DUSP4 protein could be a novel way of preventing and treating epilepsy.

Source: University of Illinois

Epileptic seizures often originate in small, localized areas of the brain where neurons abnormally fire in unison. These electrical impulses disrupt proper brain functioning and cause seizures. But what makes regions where seizures start different from parts of the brain where electrical impulses remain normal? More importantly, what prevents these epileptic centers from growing?

Researchers have made a breakthrough genetic discovery into the cause of a spectrum of severe neurological conditions.

A research study, led by the Murdoch Children’s Research Institute (MCRI) and gracing the cover of and published in the October edition of Human Mutation, found two new in the KIF1A gene cause rare nerve disorders.

MCRI researcher Dr. Simranpreet Kaur said mutations in the KIF1A gene caused ‘traffic jams’ in , called neurons, triggering a devastating range of progressive brain disorders. KIF1A-Associated Neurological Disorders (KAND) affects about 300 children worldwide.

Imagine if your manager could know whether you actually paid attention in your last Zoom meeting. Or, imagine if you could prepare your next presentation using only your thoughts. These scenarios might soon become a reality thanks to the development of brain-computer interfaces (BCIs).

To put it in the simplest terms, think of a BCI as a bridge between your brain and an external device. As of today, we mostly rely on electroencephalography (EEG) — a collection of methods for monitoring the electrical activity of the brain — to do this. But, that’s changing. By leveraging multiple sensors and complex algorithms, it’s now becoming possible to analyze brain signals and extract relevant brain patterns. Brain activity can then be recorded by a non-invasive device — no surgical intervention needed. In fact, the majority of existing and mainstream BCIs are non-invasive, such as wearable headbands and earbuds.

The development of BCI technology was initially focused on helping paralyzed people control assistive devices using their thoughts. But new use cases are being identified all the time. For example, BCIs can now be used as a neurofeedback training tool to improve cognitive performance. I expect to see a growing number of professionals leveraging BCI tools to improve their performance at work. For example, your BCI could detect that your attention level is too low compared with the importance of a given meeting or task and trigger an alert. It could also adapt the lighting of your office based on how stressed you are, or prevent you from using your company car if drowsiness is detected.

One of the most remarkable recent advances in biomedical research has been the development of highly targeted gene-editing methods such as CRISPR that can add, remove, or change a gene within a cell with great precision. The method is already being tested or used for the treatment of patients with sickle cell anemia and cancers such as multiple myeloma and liposarcoma, and today, its creators Emmanuelle Charpentier and Jennifer Doudna received the Nobel Prize in chemistry.

While is remarkably precise in finding and altering genes, there is still no way to target treatment to specific locations in the body. The treatments tested so far involve removing or immune system T cells from the body to modify them, and then infusing them back into a patient to repopulate the bloodstream or reconstitute an immune response—an expensive and time-consuming process.

Building on the accomplishments of Charpentier and Doudna, Tufts researchers have for the first time devised a way to directly deliver gene-editing packages efficiently across the and into specific regions of the brain, into immune system cells, or to specific tissues and organs in mouse models. These applications could open up an entirely new line of strategy in the treatment of neurological conditions, as well as cancer, infectious disease, and autoimmune diseases.